Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVO-DROMORAN vs AMIKACIN SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levo-dromoran (levorphanol) is a potent opioid agonist primarily at mu-opioid receptors, with additional agonist activity at kappa and delta opioid receptors. It also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic effects.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Management of moderate to severe pain,Preoperative sedation and anesthesia adjunct,Treatment of opioid dependence (off-label)
FDA-approved: Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus) when other antibiotics are ineffective or contraindicated.,Off-label: Used in combination for enterococcal endocarditis, mycobacterial infections (e.g., tuberculosis), and severe neonatal sepsis.
2 mg orally every 6-8 hours as needed for pain; 2-4 mg intramuscularly or subcutaneously every 6-8 hours; intravenous administration: 1-2 mg slowly (over 2-3 minutes) every 6-8 hours.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
Terminal elimination half-life is 15-30 hours (mean 22 hours) in adults; prolonged in hepatic or renal impairment, requiring dose adjustment.
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
Primarily hepatic via glucuronidation (UGT2B7) and N-demethylation (CYP3A4). Active metabolite: norlevorphanol.
Amikacin is not significantly metabolized; it is excreted unchanged primarily by glomerular filtration. Minimal hepatic metabolism.
Primarily renal (approximately 60% as unchanged drug and metabolites); biliary/fecal elimination accounts for about 30%.
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Approximately 60-70% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0-11% (low binding to albumin).
3-5 L/kg, indicating extensive tissue distribution beyond plasma volume.
0.25-0.4 L/kg; approximates extracellular fluid volume; increased in edema, decreased in dehydration.
Oral bioavailability is about 40-60% due to first-pass metabolism; rectal bioavailability is approximately 50-70%.
IM: nearly 100% (rapid and complete).
For GFR 30-50 m L/min: administer every 8-12 hours; GFR 10-29 m L/min: administer every 12-18 hours; GFR <10 m L/min: administer every 24 hours or consider alternative.
Cr Cl 20-50 m L/min: 7.5 mg/kg every 24 hours; Cr Cl 10-20 m L/min: 7.5 mg/kg every 48 hours; Cr Cl <10 m L/min: 7.5 mg/kg every 72-96 hours; hemodialysis: 7.5 mg/kg post-dialysis with monitoring.
Child-Pugh Class A (mild): no adjustment necessary; Child-Pugh Class B (moderate): reduce dose by 25-50%; Child-Pugh Class C (severe): avoid use or reduce dose by 75% with extended dosing interval.
No dose adjustment required for hepatic impairment; monitor drug levels if severe dysfunction.
Oral: 0.04-0.08 mg/kg/dose every 6-8 hours; Parenteral: 0.02-0.04 mg/kg/dose every 6-8 hours. Maximum single dose: 2 mg. Not recommended for children under 6 months.
Neonates <7 days: 15-20 mg/kg IV every 24-48 hours; neonates 7-28 days: 15 mg/kg every 24 hours; infants/children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day.
Initiate at 25-50% of adult dose (e.g., 1 mg orally every 6-8 hours) due to increased sensitivity and renal clearance decline; titrate cautiously.
Reduce initial dose based on renal function; usual dose 7.5 mg/kg every 24-48 hours with close monitoring of serum creatinine and drug levels due to age-related decreased GFR.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants.
WARNING: Amikacin can cause neurotoxicity, ototoxicity, and nephrotoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity may be irreversible and can occur even after drug discontinuation. Monitor renal function and drug levels closely.
Risk of respiratory depression, hypotension, bradycardia, increased intracranial pressure, seizures, serotonin syndrome, adrenal insufficiency, severe hypotension, and opioid-induced hyperalgesia. Avoid abrupt discontinuation.
Nephrotoxicity: Risk increased with advanced age, pre-existing renal impairment, concomitant use of other nephrotoxic drugs (e.g., amphotericin B, cyclosporine, NSAIDs).,Ototoxicity: Can cause irreversible bilateral hearing loss, tinnitus, and vestibular damage. Monitor audiometry in patients with risk factors.,Neuromuscular blockade: May exacerbate weakness in patients with neuromuscular disorders (e.g., myasthenia gravis, Parkinsonism). Use with caution during anesthesia or with neuromuscular blocking agents.,Hypersensitivity reactions: Including rash, drug fever, and anaphylaxis.,Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms.,Pregnancy: Risk of fetal harm (ototoxicity) if administered during pregnancy.
Hypersensitivity to levorphanol or any component, significant respiratory depression, acute or severe bronchial asthma, gastrointestinal obstruction, suspected surgical abdomen, monoamine oxidase inhibitor use within 14 days.
Hypersensitivity to amikacin, other aminoglycosides, or any component of the formulation.,Preexisting severe renal impairment (unless life-threatening infection and no alternative).,Concurrent use of other nephrotoxic or ototoxic drugs (relative contraindication).,Myasthenia gravis (caution; neuromuscular blocking effect).
Avoid grapefruit and grapefruit juice as they may increase levorphanol levels. Alcohol and any foods that cause CNS depression should be avoided. Maintenance of adequate hydration and fiber intake is recommended to mitigate constipation.
No significant food interactions. Avoid alcohol as it may increase side effects like dizziness.
First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid prolonged use.
Aminoglycosides including amikacin have been associated with fetal ototoxicity and nephrotoxicity when administered during pregnancy. There is a potential for eighth cranial nerve damage and renal impairment in the fetus, particularly during the second and third trimesters. Animal studies have shown evidence of harm, but controlled human studies are lacking. Use only if clearly needed and if safer alternatives are unavailable.
Excreted into breast milk; M/P ratio not established. Use with caution; monitor infant for sedation and respiratory depression. American Academy of Pediatrics recommends avoiding due to potential for infant toxicity.
Amikacin is excreted into human milk in low concentrations. The milk-to-plasma ratio is approximately 0.1–0.2. Due to low oral bioavailability from the gastrointestinal tract, systemic effects in the breastfed infant are unlikely. However, caution is advised due to the potential for altered infant gut flora and direct mucosal irritation. Use only if benefits outweigh risks.
Increased clearance during pregnancy may require dose adjustments; individualize based on pain severity and maternal response. Avoid use in third trimester due to risk of neonatal respiratory depression.
Pregnancy does not typically require dosing adjustments for amikacin. However, due to increased glomerular filtration rate during pregnancy, levels may be lower; monitor drug concentrations and adjust doses to achieve therapeutic range. Standard dosing based on ideal body weight and renal function should be followed.
LEVO-DROMORAN (levorphanol) is a potent opioid agonist with NMDA antagonism, making it effective for neuropathic pain. It has a long half-life (12-16 hours) requiring careful dosing intervals to avoid accumulation. Monitor for respiratory depression, especially in elderly or opioid-naïve patients. It should not be used in patients with severe respiratory insufficiency or asthma. Due to its high potency, start at lower doses and titrate slowly. Beware of QT prolongation; obtain baseline ECG. Avoid concomitant use with MAOIs.
Monitor peak (15-30 mcg/m L) and trough (<5 mcg/m L) levels to avoid nephrotoxicity and ototoxicity. Adjust dose in renal impairment using Cr Cl. Synergy with beta-lactams for Gram-negative infections. Avoid concurrent loop diuretics.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication can cause dizziness, drowsiness, or confusion; avoid driving or operating heavy machinery.,Do not consume alcohol or other CNS depressants (e.g., benzodiazepines) while taking this drug.,Constipation is common; increase fluid intake, fiber, and consider stool softeners.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store securely away from children and pets. Dispose of unused medication via drug take-back programs.,Seek emergency care if you experience difficulty breathing, severe drowsiness, or fainting.
Take exactly as prescribed; do not skip doses or stop early.,Report any hearing loss, tinnitus, dizziness, or vertigo immediately.,Drink plenty of fluids to maintain hydration, unless contraindicated.,Avoid taking other medications without consulting your doctor, especially water pills or other antibiotics.
No interactions on record
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVO-DROMORAN vs AMIKACIN SULFATE, answered by our medical review team.
LEVO-DROMORAN is a Opioid Analgesic that works by Levo-dromoran (levorphanol) is a potent opioid agonist primarily at mu-opioid receptors, with additional agonist activity at kappa and delta opioid receptors. It also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic effects.. AMIKACIN SULFATE is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVO-DROMORAN and AMIKACIN SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVO-DROMORAN is: 2 mg orally every 6-8 hours as needed for pain; 2-4 mg intramuscularly or subcutaneously every 6-8 hours; intravenous administration: 1-2 mg slowly (over 2-3 minutes) every 6-8 hours.. The standard adult dose of AMIKACIN SULFATE is: 15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVO-DROMORAN and AMIKACIN SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVO-DROMORAN is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may cause neonatal opi. AMIKACIN SULFATE is classified as Category D/X. Aminoglycosides including amikacin have been associated with fetal ototoxicity and nephrotoxicity when administered during pregnancy. There is a potential for eighth cranial nerve . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.